Lidocaine/tetracaine topical patch - Crescita Therapeutics
Alternative Names: Enhanced Formulation - Crescita Therapeutics; Heated tetracaine/lidocaine topical patch; HLT Patch; Ralydan; Rapydan; S-Caine™ Patch; SyneraLatest Information Update: 27 Apr 2024
At a glance
- Originator ZARS
- Developer Nuvo Research
- Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Procedural pain
- Phase II Musculoskeletal pain